Good morning, myeloma world.

There are times when we write an edition of Myeloma Morning, and it turns out completely different than expected. Today's edition is a perfect example.

As we were planning today's report, we thought it would focus on two preclinical research studies examining the potential new myeloma therapies CCF642 and BDA-366.

And, yes, we do start today's report with summaries of those two studies.

But readers will be making a mistake if they stop after reading that section of today's article. Because the third study we …